Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIII) Cash & Equivalents (2019 - 2025)

P3 Health Partners (PIII) has disclosed Cash & Equivalents for 7 consecutive years, with $37.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 40.1% year-over-year to $37.7 million, compared with a TTM value of $37.7 million through Sep 2025, down 40.1%, and an annual FY2024 reading of $38.8 million, changed N/A over the prior year.
  • Cash & Equivalents was $37.7 million for Q3 2025 at P3 Health Partners, down from $38.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $110.3 million in Q1 2022 and bottomed at $4.3 million in Q3 2021.
  • Average Cash & Equivalents over 5 years is $38.5 million, with a median of $36.0 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents soared 692.27% in 2022, then plummeted 40.1% in 2025.
  • Year by year, Cash & Equivalents stood at $5.3 million in 2021, then skyrocketed by 230.13% to $17.5 million in 2022, then skyrocketed by 242.29% to $59.9 million in 2023, then crashed by 35.2% to $38.8 million in 2024, then dropped by 2.84% to $37.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for PIII at $37.7 million in Q3 2025, $38.6 million in Q2 2025, and $38.8 million in Q4 2024.